Ken Griffin Biotechnology

Citadel Advisors LLC

  • $618 Billion
  • Q3 2025

Stock List

Stock Option Type Value Options Held Last Trade Trade History
GERN
Geron Corp
CALL
$558,000
408K
Q3 2025
Added 30.49%
KOD
Kodiak Sciences Inc.
PUT
$556,000
34K
Q3 2025
New holding
AMLX
Amylyx Pharmaceuticals, Inc.
PUT
$530,000
39K
Q3 2025
Reduced 81.12%
NVCT
Nuvectis Pharma, Inc.
CALL
$525,000
87.3K
Q1 2025
New holding
PTCT
Ptc Therapeutics, Inc.
PUT
$521,000
8.5K
Q3 2025
Added 88.05%
ARQT
Arcutis Biotherapeutics, Inc.
PUT
$510,000
27.1K
Q3 2025
Added 21.84%
KMPH
Kempharm, Inc
CALL
$504,000
102K
Q3 2025
Added 67.85%
WVE
Wave Life Sciences Ltd.
PUT
$497,000
69K
Q2 2025
Reduced 47.7%
LXRX
Lexicon Pharmaceuticals, Inc.
CALL
$493,000
358K
Q3 2025
New holding
RCUS
Arcus Biosciences, Inc.
PUT
$485,000
35.7K
Q3 2025
Reduced 51.73%
KURA
Kura Oncology, Inc.
PUT
$461,000
52.1K
Q3 2025
Added 122.11%
OCUL
Ocular Therapeutix, Inc
PUT
$461,000
39.5K
Q3 2025
Added 16.74%
FOLD
Amicus Therapeutics, Inc.
PUT
$460,000
58.4K
Q3 2025
Added 38.09%
CRDF
Cardiff Oncology, Inc.
CALL
$460,000
228K
Q3 2025
New holding
QSI
Quantum Si Inc
CALL
$459,000
326K
Q3 2025
Reduced 27.09%
MRVI
Maravai Lifesciences Holdings, Inc.
CALL
$449,000
157K
Q3 2025
Reduced 85.4%
NUVL
Nuvalent, Inc.
CALL
$449,000
5.2K
Q3 2025
Reduced 52.65%
IDYA
Ideaya Biosciences, Inc.
CALL
$443,000
16.3K
Q3 2025
Reduced 27.87%
PHAT
Phathom Pharmaceuticals, Inc.
CALL
$439,000
38.4K
Q3 2025
New holding
VERA
Vera Therapeutics, Inc.
CALL
$437,000
15.1K
Q3 2025
Added 186.98%
CTMX
Cytom X Therapeutics, Inc.
CALL
$429,000
135K
Q3 2025
Added 2005.55%
TERN
Terns Pharmaceuticals, Inc.
CALL
$424,000
55.8K
Q3 2025
Reduced 59.24%
INMB
Inmune Bio, Inc.
CALL
$419,000
201K
Q1 2025
Added 94.48%
VERA
Vera Therapeutics, Inc.
PUT
$417,000
14.4K
Q3 2025
Added 186.98%
RGNX
Regenxbio Inc.
PUT
$413,000
42.9K
Q3 2025
Reduced 80.98%
PTGX
Protagonist Therapeutics, Inc
PUT
$411,000
6.2K
Q3 2025
Added 774.53%
ARCT
Arcturus Therapeutics Holdings Inc.
CALL
$409,000
22.2K
Q3 2025
Added 46.86%
GLPG
Galapagos Nv
CALL
$405,000
11.7K
Q3 2025
Added 36.41%
MDXG
Mimedx Group, Inc.
PUT
$402,000
57.7K
Q3 2025
Reduced 69.7%
TRVI
Trevi Therapeutics, Inc.
CALL
$400,000
44.8K
Q3 2025
Reduced 92.23%
TARS
Tarsus Pharmaceuticals, Inc.
CALL
$392,000
6.6K
Q3 2025
Reduced 81.12%
PEPG
Pep Gen Inc.
PUT
$389,000
84.4K
Q3 2025
New holding
DYN
Dyne Therapeutics, Inc.
CALL
$388,000
30.7K
Q3 2025
Added 261.64%
XERS
Xeris Biopharma Holdings, Inc.
PUT
$381,000
47.1K
Q3 2025
New holding
STOK
Stoke Therapeutics, Inc.
CALL
$373,000
15.9K
Q3 2025
Reduced 28.27%
LIFE
A Tyr Pharma Inc
CALL
$371,000
200K
Q2 2025
Reduced 54.36%
RZLT
Rezolute, Inc.
CALL
$369,000
39.8K
Q3 2025
Added 416.91%
INMB
Inmune Bio, Inc.
PUT
$368,000
176K
Q1 2025
Added 94.48%
ABSI
Absci Corp
PUT
$365,000
120K
Q3 2025
New holding
BMEA
Biomea Fusion, Inc.
CALL
$364,000
180K
Q3 2025
New holding
SANA
Sana Biotechnology, Inc.
CALL
$362,000
102K
Q3 2025
Added 121.72%
KURA
Kura Oncology, Inc.
CALL
$361,000
40.9K
Q3 2025
Added 122.11%
JANX
Janux Therapeutics, Inc.
PUT
$354,000
14.5K
Q3 2025
Reduced 34.79%
CPRX
Catalyst Pharmaceuticals, Inc.
CALL
$352,000
17.9K
Q3 2025
Added 53.04%
SANA
Sana Biotechnology, Inc.
PUT
$349,000
98.5K
Q3 2025
Added 121.72%
KROS
Keros Therapeutics, Inc.
CALL
$346,000
21.9K
Q3 2025
Added 669.25%
CRVS
Corvus Pharmaceuticals, Inc.
CALL
$345,000
48.2K
Q3 2025
New holding
CPRX
Catalyst Pharmaceuticals, Inc.
PUT
$344,000
17.5K
Q3 2025
Added 53.04%
OMER
Omeros Corp
CALL
$337,000
82.4K
Q3 2025
Added 149.34%
Filter Shares Options
Ken Griffin

Ken Griffin

Ken Griffin is the founder and CEO of Citadel Advisors, a successful investment firm that uses technology and data-driven approaches to investing. Griffin is known for his expertise in quantitative investing and his innovative approach to investing. He has generated strong returns for his clients over the long term.
Track Ken Griffin's portfolio
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email